Determination of ropivacaine and its metabolites in patient urine: Advantage of liquid chromatography-tandem mass spectrometry over liquid chromatography-UV detection and liquid chromatography-mass spectrometry

被引:10
作者
Abdel-Rehim, M [1 ]
Bielenstein, M
Askemark, Y
机构
[1] AstraZeneca R&D Sodertalje, DMPK, SE-15185 Sodertalje, Sweden
[2] AstraZeneca R&D Sodertalje, Bioanalyt Chem, SE-15185 Sodertalje, Sweden
关键词
urine samples; ropivacaine; 3-OH-ropivacaine; trimethoprim; LC-UV; LC-MS-MS;
D O I
10.1016/S0003-2670(03)00574-9
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Analysis of urine samples from a clinical study of ropivacaine and its metabolites, 3-hydroxyropivacaine (3-OH-ropivacaine) and PPX, by an LC-UV method showed high concentrations of 3-hydroxyropivacaine, 2-50 times higher than expected. In the study, the patients were treated with a number of drugs in combination with ropivacaine. These drugs were paracetamol, lidocaine, fentanyl, morphine and trimethoprim. When the fraction of 3-hydroxyropivacaine was collected from LC-UV and analysed by LC-MS, only a high signal at mass number 291 [3-hydroxyropivacaine (MH+)] was observed. This observation indicates that it may be a drug or a metabolite having the same mass number as 3-hydroxyropivacaine and eluting at the same retention time on the LC system that gives a high signal in UV and MS detection. The examination of the drugs given showed that trimethoprim has the same molecular weight as 3-hydroxyropivacame. The analysis of trimethoprim by LC-UV and LC-MS showed that under the given conditions it has the same retention time as 3-hydroxyropivacame. The tuning of 3-hydroxyropivacaine and trimethoprim by MS-MS showed that both substances have the same precursor ions (m/z: 291) but different product ions (m/z: 126 and 123 for 3-hydroxyropivacaine and trimethoprim, respectively). This study shows that the use of LC-MS-MS may lead to more reliable results than LC-UV and LC-MS. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:253 / 260
页数:8
相关论文
共 18 条
[1]   Determination of ropivacaine and its metabolites in human plasma using solid phase microextraction and GG-NPD/GC-MS [J].
Abdel-Rehim, M ;
Andersson, M ;
Portelius, E ;
Norsten-Höög, C ;
Blomberg, LG .
JOURNAL OF MICROCOLUMN SEPARATIONS, 2001, 13 (08) :313-321
[2]  
Abdel-Rehim M, 2000, J MICROCOLUMN SEP, V12, P308, DOI 10.1002/(SICI)1520-667X(2000)12:5<308::AID-MCS5>3.0.CO
[3]  
2-F
[4]  
Ackermann Bradley L., 2002, Current Topics in Medicinal Chemistry, V2, P53, DOI 10.2174/1568026023394605
[5]  
Arvidsson T, 1999, BIOMED CHROMATOGR, V13, P286, DOI 10.1002/(SICI)1099-0801(199906)13:4<286::AID-BMC862>3.0.CO
[6]  
2-M
[7]   Collection, storage, and filtration of in vivo study samples using 96-well filter plates to facilitate automated sample preparation and LC/MS/MS analysis [J].
Berna, M ;
Murphy, AT ;
Wilken, B ;
Ackermann, B .
ANALYTICAL CHEMISTRY, 2002, 74 (05) :1197-+
[8]  
CASTROPEREZ J, 2002, CHROMATOGR S, V55, P59, DOI DOI 10.1007/BF02493354
[9]   Determination of ropivacaine and [2H3]ropivacaine in biological samples by gas chromatography with nitrogen-phosphorus detection or mass spectrometry [J].
Engman, M ;
Neidenström, P ;
Norsten-Höög, C ;
Wiklund, SJ ;
Bondesson, U ;
Arvidsson, T .
JOURNAL OF CHROMATOGRAPHY B, 1998, 709 (01) :57-67
[10]  
FELDMAN HS, 1994, ANAESTHETIC TOXICITY